
zzso zzso zzso zzso can zzso cancer cells to zzso zzso by increasing their access and binding to zzso 

This phase I trial was designed to determine the toxicity profile, zzso and recommended phase II dose of escalating doses of the zzso zzso with weekly zzso 

In total, 32 patients were zzso zzso was zzso at 400, zzso zzso or 1000 zzso zzso on days zzso followed by zzso (20 zzso zzso on day 3 for 3 of 4 zzso zzso tolerated dose was determined to be 800 zzso zzso of zzso zzso zzso were grade 3 zzso zzso out of zzso and fatigue (one out of zzso at 1000 zzso zzso zzso grade 3/4 zzso included zzso toxicity and zzso zzso zzso activity in 24 zzso patients included two partial responses zzso and prostate zzso Two patients with melanoma had stable disease for zzso or zzso zzso zzso zzso changes in peripheral blood zzso and zzso cells were zzso zzso zzso seemed to correlate with zzso zzso zzso 

These findings suggest that zzso can be combined with weekly zzso in this schedule at a dose of 800 zzso zzso The zzso expression may be a marker zzso of zzso zzso zzso activity of this regimen in breast cancer, prostate cancer, and melanoma seems zzso 

